T. Rowe Price Associates’s ALX Oncology ALXO Stock Holding History

T. Rowe Price Associates’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,622	Closed	-$7K	–	3062
2025 Q1	$7K	Hold	10,622	–	–	﹤0.01%	3029
2024 Q4	$18K	Hold	10,622	–	–	﹤0.01%	2996
2024 Q3	$20K	Hold	10,622	–	–	﹤0.01%	2988
2024 Q2	$65K	Sell	10,622 -222,147	-95%	-$2.73M	﹤0.01%	2820
2024 Q1	$2.6M	Sell	232,769 -310,474	-57%	-$4.36M	﹤0.01%	1454
2023 Q4	$8.09M	Buy	+543,243	New	+$5.15M	﹤0.01%	1136
2021 Q4	–	Sell	-4,110	Closed	-$304K	–	2978
2021 Q3	$304K	Buy	4,110 +44	+1%	+$2.93K	﹤0.01%	2576
2021 Q2	$222K	Sell	4,066 -408	-9%	-$24.4K	﹤0.01%	2691
2021 Q1	$330K	Buy	+4,474	New	+$352K	﹤0.01%	2529
2020 Q4	–	Sell	-223,654	Closed	-$8.44M	–	2665
2020 Q3	$8.44M	Buy	+223,654	New	+$8.79M	﹤0.01%	1332

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

T. Rowe Price Associates's ALXO Position: Q2 2025 in Review

T. Rowe Price Associates sold out of ALX Oncology (ALXO) in Q2 2025, closing a stake of 10,622 shares — an estimated $7K sold.

T. Rowe Price Associates first reported a position in ALXO in Q3 2020 and held it in 10 quarters. The position peaked at $8.44M in Q3 2020. 61 funds tracked by Wall St. Rank hold ALXO as of Q2 2025.

T. Rowe Price Associates reported no remaining ALX Oncology position as of Q2 2025 after selling out during the quarter.
T. Rowe Price Associates sold 10,622 ALX Oncology shares in Q2 2025, an estimated $7K.
T. Rowe Price Associates first reported a position in ALX Oncology in Q3 2020 and held it in 10 quarters.
T. Rowe Price Associates's ALX Oncology position peaked at $8.44M in Q3 2020.
61 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.